126 related articles for article (PubMed ID: 28913367)
21. Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma.
Liu L; Zhang W; Qi X; Li H; Yu J; Wei S; Hao X; Ren X
Clin Cancer Res; 2012 Mar; 18(6):1751-9. PubMed ID: 22275504
[TBL] [Abstract][Full Text] [Related]
22. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors.
Di Pucchio T; Pilla L; Capone I; Ferrantini M; Montefiore E; Urbani F; Patuzzo R; Pennacchioli E; Santinami M; Cova A; Sovena G; Arienti F; Lombardo C; Lombardi A; Caporaso P; D'Atri S; Marchetti P; Bonmassar E; Parmiani G; Belardelli F; Rivoltini L
Cancer Res; 2006 May; 66(9):4943-51. PubMed ID: 16651452
[TBL] [Abstract][Full Text] [Related]
23. A randomised phase II trial of 1 month versus 1 year of adjuvant high-dose interferon α-2b in high-risk acral melanoma patients.
Mao L; Si L; Chi Z; Cui C; Sheng X; Li S; Tang B; Guo J
Eur J Cancer; 2011 Jul; 47(10):1498-503. PubMed ID: 21493058
[TBL] [Abstract][Full Text] [Related]
24. Paucity of tumor-infiltrating lymphocytes is an unfavorable prognosticator and predicts lymph node metastases in cutaneous melanoma patients.
Donizy P; Kaczorowski M; Halon A; Leskiewicz M; Kozyra C; Matkowski R
Anticancer Res; 2015 Jan; 35(1):351-8. PubMed ID: 25550571
[TBL] [Abstract][Full Text] [Related]
25. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801.
Kirkwood JM; Ibrahim JG; Sosman JA; Sondak VK; Agarwala SS; Ernstoff MS; Rao U
J Clin Oncol; 2001 May; 19(9):2370-80. PubMed ID: 11331315
[TBL] [Abstract][Full Text] [Related]
26. Preoperative NLR for predicting survival rate after radical resection combined with adjuvant immunotherapy with CIK and postoperative chemotherapy in gastric cancer.
Li Y; Wang C; Xu M; Kong C; Qu A; Zhang M; Zheng Z; Zhang G
J Cancer Res Clin Oncol; 2017 May; 143(5):861-871. PubMed ID: 28108815
[TBL] [Abstract][Full Text] [Related]
27. Adjuvant therapy in melanoma.
Mohr P; Weichenthal M; Hauschild A
Onkologie; 2003 Jun; 26(3):227-33. PubMed ID: 12845206
[TBL] [Abstract][Full Text] [Related]
28. Autologous cytokine-induced killer cell immunotherapy in lung cancer: a phase II clinical study.
Li R; Wang C; Liu L; Du C; Cao S; Yu J; Wang SE; Hao X; Ren X; Li H
Cancer Immunol Immunother; 2012 Nov; 61(11):2125-33. PubMed ID: 22581306
[TBL] [Abstract][Full Text] [Related]
29. Chemotherapy in combination with cytokine-induced killer cell transfusion: An effective therapeutic option for patients with extensive stage small cell lung cancer.
Huang J; Kan Q; Lan ; Zhao X; Zhang Z; Yang S; Li H; Wang L; Xu L; Cheng Z; Zhang Y
Int Immunopharmacol; 2017 May; 46():170-177. PubMed ID: 28292730
[TBL] [Abstract][Full Text] [Related]
30. Adjuvant therapy of stage IIIb melanoma with interferon alfa-2b: clinical and immunological relevance.
Doveil GC; Fierro MT; Novelli M; Appino A; Bertero M; Quaglino P; Bernengo MG
Dermatology; 1995; 191(3):234-9. PubMed ID: 8534942
[TBL] [Abstract][Full Text] [Related]
31. Relationship between responsiveness of cancer cells to Oncostatin M and/or IL-6 and survival of stage III melanoma patients treated with tumour-infiltrating lymphocytes.
Lacreusette A; Lartigue A; Nguyen JM; Barbieux I; Pandolfino MC; Paris F; Khammari A; Dréno B; Jacques Y; Blanchard F; Godard A
J Pathol; 2008 Dec; 216(4):451-9. PubMed ID: 18798220
[TBL] [Abstract][Full Text] [Related]
32. Final Results of the Sunbelt Melanoma Trial: A Multi-Institutional Prospective Randomized Phase III Study Evaluating the Role of Adjuvant High-Dose Interferon Alfa-2b and Completion Lymph Node Dissection for Patients Staged by Sentinel Lymph Node Biopsy.
McMasters KM; Egger ME; Edwards MJ; Ross MI; Reintgen DS; Noyes RD; Martin RC; Goydos JS; Beitsch PD; Urist MM; Ariyan S; Sussman JJ; Davidson BS; Gershenwald JE; Hagendoorn LJ; Stromberg AJ; Scoggins CR
J Clin Oncol; 2016 Apr; 34(10):1079-86. PubMed ID: 26858331
[TBL] [Abstract][Full Text] [Related]
33. Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991.
Eggermont AM; Suciu S; Testori A; Kruit WH; Marsden J; Punt CJ; Santinami M; Salès F; Schadendorf D; Patel P; Dummer R; Robert C; Keilholz U; Yver A; Spatz A
Eur J Cancer; 2012 Jan; 48(2):218-25. PubMed ID: 22056637
[TBL] [Abstract][Full Text] [Related]
34. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients.
Besser MJ; Shapira-Frommer R; Treves AJ; Zippel D; Itzhaki O; Hershkovitz L; Levy D; Kubi A; Hovav E; Chermoshniuk N; Shalmon B; Hardan I; Catane R; Markel G; Apter S; Ben-Nun A; Kuchuk I; Shimoni A; Nagler A; Schachter J
Clin Cancer Res; 2010 May; 16(9):2646-55. PubMed ID: 20406835
[TBL] [Abstract][Full Text] [Related]
35. Dendritic cell-activated cytokine-induced killer cells enhance the anti-tumor effect of chemotherapy on non-small cell lung cancer in patients after surgery.
Li H; Wang C; Yu J; Cao S; Wei F; Zhang W; Han Y; Ren XB
Cytotherapy; 2009; 11(8):1076-83. PubMed ID: 19929470
[TBL] [Abstract][Full Text] [Related]
36. Fluorouracil and leucovorin with or without interferon alfa-2a as adjuvant treatment, in patients with high-risk colon cancer: a randomized phase III study conducted by the Hellenic Cooperative Oncology Group.
Fountzilas G; Zisiadis A; Dafni U; Konstantaras C; Hatzitheoharis G; Papavramidis S; Bousoulegas A; Basdanis G; Giannoulis E; Dokmetzioglou J; Katsohis C; Nenopoulou E; Karvounis N; Briassoulis E; Aravantinos G; Kosmidis P; Skarlos D; Pavlidis N
Oncology; 2000 Apr; 58(3):227-36. PubMed ID: 10765125
[TBL] [Abstract][Full Text] [Related]
37. Influence of the number and interval of treatment cycles on cytokine-induced killer cells and their adjuvant therapeutic effects in advanced non-small-cell lung cancer (NSCLC).
Gu Y; Lv H; Zhao J; Li Q; Mu G; Li J; Wuyang J; Lou G; Wang R; Zhang Y; Huang X
Int Immunopharmacol; 2017 Sep; 50():263-269. PubMed ID: 28711032
[TBL] [Abstract][Full Text] [Related]
38. Maintenance therapy with autologous cytokine-induced killer cells in patients with advanced epithelial ovarian cancer after first-line treatment.
Liu J; Li H; Cao S; Zhang X; Yu J; Qi J; An X; Yu W; Ren X; Hao X
J Immunother; 2014; 37(2):115-22. PubMed ID: 24509174
[TBL] [Abstract][Full Text] [Related]
39. Prognostic and predictive value of YKL-40 in stage IIB-III melanoma.
Krogh M; Christensen I; Bouwhuis M; Johansen JS; Nørgaard P; Schmidt H; Hansson J; Suciu S; Eggermont AM; Bastholt L;
Melanoma Res; 2016 Aug; 26(4):367-76. PubMed ID: 27076041
[TBL] [Abstract][Full Text] [Related]
40. White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy.
Weber J; Atkins M; Hwu P; Radvanyi L; Sznol M; Yee C;
Clin Cancer Res; 2011 Apr; 17(7):1664-73. PubMed ID: 21325070
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
